Metacognitive interpersonal therapy in group versus TAU + waiting list for young adults with personality disorders: Randomized clinical trial.

2021 ◽  
Author(s):  
Raffaele Popolo ◽  
Angus MacBeth ◽  
Luana Lazzerini ◽  
Stefano Brunello ◽  
Gloria Venturelli ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Young Adults ◽  
Personality Disorders ◽  
Randomized Clinical Trial ◽  
Group Versus ◽  
Waiting List ◽  
Interpersonal Therapy ◽  
Metacognitive Interpersonal Therapy

scholarly journals Metacognitive interpersonal therapy in group: a feasibility study

2018 ◽  
Vol 21 (3) ◽  
Author(s):  
Raffaele Popolo ◽  
Angus MacBeth ◽  
Stefano Brunello ◽  
Flaviano Canfora ◽  
Ercan Ozdemir ◽  
...  
Keyword(s):  
Personality Disorders ◽  
Group Intervention ◽  
Emotion Dysregulation ◽  
Controlled Trial ◽  
Mental States ◽  
Evidence Base ◽  
Emotional Dysregulation ◽  
Drop Out ◽  
Interpersonal Therapy ◽  
Metacognitive Interpersonal Therapy

Patients with personality disorders (PDs) other than borderline, with prominent features of social inhibition and over-regulation of emotions, are in need of specialized treatments. Individuals present with poor metacognition, that is the capacity to understand mental states and use psychological knowledge for the sake of purposeful problem solving; and are guided by maladaptive interpersonal schemas. We developed a short-term group intervention, Metacognitive Interpersonal Therapy in Groups (MIT-G), incorporating psychoeducational and experiential elements, to help these individuals become more aware of their drives when interacting with others; and to help them adopt more flexible behaviors via improvements in metacognition. We present results of an effectiveness study, evaluating whether we could replicate the initial positive results of our first pilot randomized controlled trial. Seventeen young adults outpatients with personality disorders were included in the 16 session program. Effect sizes were calculated for change from baseline to treatment end for the primary outcome, symptoms and functioning (Clinical Outcomes in Routine Evaluation Outcome Measure) and then for one putative mechanism of change – metacognition. Emotional dysregulation and alexithymia were also assessed. Qualitative evaluations of the acceptability and subjective impact of the treatment were also performed. MIT-G was acceptable to participants. There were medium to large magnitude changes from pre- to post- treatment on wellbeing, emotion dysregulation, alexithymia and metacognition. These gains were maintained at follow-up. There was evidence of clinically significant change on key variables. MIT-G appears acceptable to patients, as evidenced by the absence of drop-out from treatment. In light of the positive outcomes of this study and the expanding evidence base, MIT-G is a candidate for dissemination and investigations in larger trials as a possible effective intervention for PDs characterized by tendencies to overcontrol.

Author response for "A Phase 3 Randomized Clinical Trial using Once‐Weekly GLP ‐1 Receptor Agonist in Adolescents and Young Adults with Hypothalamic Obesity"

2020 ◽  
Author(s):  
Christian L. Roth ◽  
Francisco A. Perez ◽  
Kathryn B. Whitlock ◽  
Clinton Elfers ◽  
Jack A. Yanovski ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Young Adults ◽  
Randomized Clinical Trial ◽  
Receptor Agonist ◽  
Adolescents And Young Adults ◽  
Author Response ◽  
Hypothalamic Obesity ◽  
Phase 3

Mentalization as a moderator of treatment effects: Findings from a randomized clinical trial for personality disorders

2013 ◽  
Vol 23 (6) ◽  
pp. 674-689 ◽  
Author(s):  
Frida Slagstad Gullestad ◽  
Merete Selsbakk Johansen ◽  
Per Høglend ◽  
Sigmund Karterud ◽  
Theresa Wilberg
Keyword(s):  
Clinical Trial ◽  
Personality Disorders ◽  
Randomized Clinical Trial ◽  
Treatment Effects
Sign in / Sign up

Export Citation Format

Share Document